Evaluation of Serum Urocortin 2 Levels in Patients with Hypertension
- 10 January 2020
- journal article
- research article
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 27 (1) , 35-42
Abstract
Urocortin 2 (UCN2), is an endogenous stress-related peptide belonging to the corticotropin-releasing factor (CRF) family, has a major role in the pathogenesis of congestive heart failure, ischemic heart disease, and hypertension.Keywords
This publication has 25 references indexed in Scilit:
- Interactions of Enhanced Urocortin 2 and Mineralocorticoid Receptor Antagonism in Experimental Heart FailureCirculation: Heart Failure, 2013
- Urocortin 2 sustains haemodynamic and renal function during introduction of beta-blockade in experimental heart failureJournal Of Hypertension, 2011
- cAMP‐ and Ca2+/calmodulin‐dependent protein kinases mediate inotropic, lusitropic and arrhythmogenic effects of urocortin 2 in mouse ventricular myocytesBritish Journal of Pharmacology, 2010
- Plasma urocortin in acute myocardial infarction patientsEuropean Journal of Clinical Investigation, 2010
- Immediate and Sustained Blood Pressure Lowering by Urocortin 2Hypertension, 2009
- Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failureClinical Science, 2008
- Urocortin-induced relaxation in the human internal mammary arteryCardiovascular Research, 2005
- Intravenous urocortin II decreases blood pressure through CRF2 receptor in ratsRegulatory Peptides, 2003
- Urocortin‐induced endothelium‐dependent relaxation of rat coronary artery: role of nitric oxide and K+ channelsBritish Journal of Pharmacology, 2002
- Corticotropin-Releasing Factor Type 1 and Type 2α Receptors Regulate Phosphorylation of Calcium/Cyclic Adenosine 3′,5′-Monophosphate Response Element-Binding Protein and Activation of p42/p44 Mitogen-Activated Protein KinaseEndocrinology, 1999